Breaking Finance News

EKF Diagnostics Holdings PLC (LON:EKF) has been reiterated to Corporate in a report by N+1 Singer earlier today.

Yesterday EKF Diagnostics Holdings PLC (LON:EKF) traded 15.15% higher at 16.63GBX. The company’s 50-day moving average is 14.89GBX and its 200-day moving average is 13.22GBX. The last stock close price is up 27.39% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,267,757 shares of the stock were exchanged, up from an average trading volume of 717,786

N+1 Singer has reiterated EKF Diagnostics Holdings PLC (LON:EKF) to Corporate in a statement released on 10/07/2016.

Previously on Monday September 12, 2016, N+1 Singer reported about EKF Diagnostics Holdings PLC (LON:EKF) raised the target price from 18.00GBX to 19.00GBX. At the time, this indicated a possible upside of 0.20%.

See Chart Below

EKF Diagnostics Holdings PLC (LON:EKF)

EKF Diagnostics Holdings PLC has a 52 week low of 7.00GBX and a 52 week high of 23.45GBX The company’s market cap is currently 0 GBX.

In addition to N+1 Singer reporting its target price, a total of 2 firms have reported on the stock. The consensus target price is 18.50GBX with 0 firms rating the stock a strong buy, 1 firm rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About EKF Diagnostics Holdings PLC (LON:EKF)

EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. The Company's Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen C-Line and Biosen S-Line, STAT-Site M B-HB analyzer, sTNFR1 biomarker test kits and Altair 240.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *